These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 22325175)

  • 1. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
    Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Two Calprotectin Rapid Tests in Daily Routine.
    Schulz C; Wex T; Arnim UV; Malfertheiner P
    Clin Lab; 2016 Jul; 62(7):1249-1254. PubMed ID: 28164652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
    Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up.
    Delefortrie Q; Schatt P; Grimmelprez A; Gohy P; Deltour D; Collard G; Vankerkhoven P
    Clin Biochem; 2016 Feb; 49(3):268-73. PubMed ID: 26506117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
    Li XG; Lu YM; Gu F; Yang XL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal calprotectin concentrations in gastrointestinal diseases.
    Wang S; Wang Z; Shi H; Heng L; Juan W; Yuan B; Wu X; Wang F
    J Int Med Res; 2013 Aug; 41(4):1357-61. PubMed ID: 23723365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity.
    Heida A; Knol M; Kobold AM; Bootsman J; Dijkstra G; van Rheenen PF
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1742-1749.e2. PubMed ID: 28606846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
    Keohane J; O'Mahony C; O'Mahony L; O'Mahony S; Quigley EM; Shanahan F
    Am J Gastroenterol; 2010 Aug; 105(8):1788, 1789-94; quiz 1795. PubMed ID: 20389294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease.
    Eder P; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
    Pol Arch Med Wewn; 2008 Nov; 118(11):622-6. PubMed ID: 19140565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.